EA201171197A8 - Замещенные производные азоантрацена, фармацевтические композиции и способы их применения - Google Patents

Замещенные производные азоантрацена, фармацевтические композиции и способы их применения

Info

Publication number
EA201171197A8
EA201171197A8 EA201171197A EA201171197A EA201171197A8 EA 201171197 A8 EA201171197 A8 EA 201171197A8 EA 201171197 A EA201171197 A EA 201171197A EA 201171197 A EA201171197 A EA 201171197A EA 201171197 A8 EA201171197 A8 EA 201171197A8
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
azoanthracene
methods
application
substituted derivatives
Prior art date
Application number
EA201171197A
Other languages
English (en)
Other versions
EA201171197A1 (ru
EA023430B1 (ru
Inventor
Аднан М.М. Мджалли
Кристофер Бем
Дэниел П. Кристен
Дхарма Рао Полисетти
Джеймс Куада
Чидамбаресваран Калпати Сантош
Муралидхар Бондлела
Мустафа Гузель
Равиндра Редди Яррагунта
Деви Редди Гохимуккула
Роберт Карл Эндрюс
Стефен Томас Дэвис
Томас Скотт Йокум
Дженнифер Л.Р. Фримен
Original Assignee
Транстек Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Транстек Фарма, Инк. filed Critical Транстек Фарма, Инк.
Publication of EA201171197A1 publication Critical patent/EA201171197A1/ru
Publication of EA201171197A8 publication Critical patent/EA201171197A8/ru
Publication of EA023430B1 publication Critical patent/EA023430B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к замещенным производным азоантрацена или их фармацевтически приемлемым солям, которые модулируют рецептор GLP-1R человека и которые могут быть применимы при лечении заболеваний, нарушений или состояний, при которых модуляция рецептора GLP-1 человека является полезной, таких как сахарный диабет 2 типа. Изобретение также относится к фармацевтическим композициям, содержащим эти соединения, и к применению этих соединений и композиций при лечении таких заболеваний, нарушений или состояний, при которых модуляция рецептора GLP-1 человека является полезной.
EA201171197A 2009-03-30 2010-03-30 Замещенные производные азоантрацена, фармацевтические композиции и способы их применения EA023430B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16452309P 2009-03-30 2009-03-30
US30934810P 2010-03-01 2010-03-01
PCT/US2010/029172 WO2010114824A1 (en) 2009-03-30 2010-03-30 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Publications (3)

Publication Number Publication Date
EA201171197A1 EA201171197A1 (ru) 2012-04-30
EA201171197A8 true EA201171197A8 (ru) 2014-10-30
EA023430B1 EA023430B1 (ru) 2016-06-30

Family

ID=42828657

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171197A EA023430B1 (ru) 2009-03-30 2010-03-30 Замещенные производные азоантрацена, фармацевтические композиции и способы их применения

Country Status (18)

Country Link
US (3) US8383644B2 (ru)
EP (1) EP2413693B1 (ru)
JP (1) JP5755217B2 (ru)
KR (1) KR101732978B1 (ru)
CN (1) CN102378574B (ru)
AU (1) AU2010232750B2 (ru)
BR (1) BRPI1013579A2 (ru)
CA (1) CA2757084C (ru)
DK (1) DK2413693T3 (ru)
EA (1) EA023430B1 (ru)
ES (1) ES2553645T3 (ru)
HK (1) HK1164050A1 (ru)
IL (1) IL214822A (ru)
MA (1) MA33219B1 (ru)
MX (1) MX2011010347A (ru)
SG (1) SG174205A1 (ru)
TN (1) TN2011000437A1 (ru)
WO (1) WO2010114824A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5755217B2 (ja) 2009-03-30 2015-07-29 トランステック・ファーマ，エルエルシー 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
WO2013059215A1 (en) 2011-10-17 2013-04-25 Biotheryx, Inc. Substituted biaryl alkyl amides
CN104968341B (zh) * 2013-01-17 2020-06-09 Vtv治疗有限责任公司 Glp1r激动剂和二甲双胍的组合及其在制备治疗2型糖尿病和其他障碍的药物中的用途
EP3549582A3 (en) 2014-08-29 2020-01-01 The Board of Regents of The University of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2019103060A1 (ja) * 2017-11-22 2019-05-31 第一三共株式会社 縮合三環化合物
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2021523877A (ja) * 2018-05-08 2021-09-09 ブイティーブイ・セラピューティクス・エルエルシー Ｇｌｐ１ｒアゴニストの治療的使用
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
US20230174547A1 (en) * 2020-04-01 2023-06-08 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Pharmaceutically acceptable acid salt of free base of glp1 receptor agonist, and preparation method therefor
JP2023528565A (ja) 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
TW202206412A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 製備（ｓ）－２－胺基－３－（４－（２，３－二甲基吡啶－４－基）苯基）丙酸甲酯及其鹽酸鹽的方法
TW202206420A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 用於製備glp-1受體促效劑的中間體和方法
TW202210461A (zh) 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種（ｓ）—２—胺基—３—（４—（２，３—二甲基吡啶—４—基）苯基）丙酸甲酯二酸鹽的製備方法
CN115697968B (zh) * 2020-05-28 2024-03-29 杭州中美华东制药有限公司 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
TW202210487A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種ｇｌｐ－１受體激動劑游離鹼的製備方法
TW202210486A (zh) 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種製備ｇｌｐ—１受體激動劑的方法
WO2022007979A1 (zh) 2020-09-01 2022-01-13 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
US20230382921A1 (en) * 2020-09-21 2023-11-30 Vtv Therapeutics Llc Amorphous Form of Isoquinoline Derivative
WO2022076503A1 (en) * 2020-10-08 2022-04-14 Eli Lilly And Company 6-methoxy-3,4-dihydro-1h-isoquinoline compounds useful in the treatment of diabetes
CN116348464A (zh) 2020-10-12 2023-06-27 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
CA3200245A1 (en) 2020-11-27 2022-06-02 Junjun Wu Benzimidazole derivative and preparation method therefor and medical use thereof
EP4317142A1 (en) 2021-03-22 2024-02-07 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法
CN117500808A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
CN117362283A (zh) 2021-06-24 2024-01-09 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
WO2023029979A1 (zh) * 2021-09-03 2023-03-09 杭州中美华东制药有限公司 Glp-1受体激动剂中间体的制备方法
CA3231153A1 (en) 2021-09-08 2023-03-16 Kosuke Takemoto Medicine for prevention and treatment of diseases linked to anti-obesity activity
CA3233453A1 (en) 2021-09-28 2023-04-06 Meimei Chen Solid composition of glp-1 receptor agonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795265A (fr) * 1972-02-09 1973-08-09 Philips Nv Nouveaux derives de quinoleine a activite pharmacologique
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
EP1379523B1 (en) * 2001-03-27 2005-07-27 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
US6933303B2 (en) 2001-10-19 2005-08-23 Transtech Pharma, Inc. Heteroaryl-fused nitrogen heterocycles as therapeutic agents
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
CN100432056C (zh) 2003-03-26 2008-11-12 埃科特莱茵药品有限公司 四氢异喹啉基乙酰胺衍生物作为阿立新受体拮抗剂的应用
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
US8466296B2 (en) * 2007-03-26 2013-06-18 Ligand Pharmaceuticals Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones
CN101959405B (zh) * 2008-03-07 2014-07-02 转化技术制药有限责任公司 治疗糖尿病的氧杂二氮杂蒽化合物
WO2009126709A1 (en) 2008-04-09 2009-10-15 Transtech Pharma, Inc. Ligands for the glp-1 receptor and methods for discovery thereof
JP5755217B2 (ja) 2009-03-30 2015-07-29 トランステック・ファーマ，エルエルシー 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
WO2011156655A2 (en) 2010-06-09 2011-12-15 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
US20110160198A1 (en) 2011-06-30
MX2011010347A (es) 2011-11-29
JP5755217B2 (ja) 2015-07-29
IL214822A0 (en) 2011-11-30
WO2010114824A8 (en) 2011-10-06
CN102378574B (zh) 2013-11-20
WO2010114824A1 (en) 2010-10-07
JP2012522060A (ja) 2012-09-20
US8383644B2 (en) 2013-02-26
CN102378574A (zh) 2012-03-14
AU2010232750B2 (en) 2015-10-29
US20150148539A1 (en) 2015-05-28
CA2757084C (en) 2017-08-29
CA2757084A1 (en) 2010-10-07
EA201171197A1 (ru) 2012-04-30
TN2011000437A1 (en) 2013-03-27
EP2413693A1 (en) 2012-02-08
US20130096150A1 (en) 2013-04-18
HK1164050A1 (en) 2012-09-21
AU2010232750A1 (en) 2011-09-08
SG174205A1 (en) 2011-10-28
DK2413693T3 (en) 2015-11-16
EP2413693B1 (en) 2015-09-09
IL214822A (en) 2016-08-31
MA33219B1 (fr) 2012-04-02
US8987295B2 (en) 2015-03-24
ES2553645T3 (es) 2015-12-10
EP2413693A4 (en) 2012-08-22
EA023430B1 (ru) 2016-06-30
US9175003B2 (en) 2015-11-03
KR101732978B1 (ko) 2017-05-08
KR20120006506A (ko) 2012-01-18
BRPI1013579A2 (pt) 2020-11-03

Similar Documents

Publication Publication Date Title
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
EA201170705A1 (ru) Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
EA200701471A1 (ru) Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма и лечение ассоциированных с ним расстройств
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
EA201190138A1 (ru) Производные фуропиримидиндиона в качестве модуляторов trpa1
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM